Wick W E
Appl Microbiol. 1967 Jul;15(4):765-9. doi: 10.1128/am.15.4.765-769.1967.
A new antibiotic, structurally related to cephaloglycin, has been assigned the generic name cephalexin, 7-(D-alpha-amino-alpha-phenylacetamido)-3-methyl-3-cephem-5-carboxylic acid. In vitro antimicrobial activity of cephalexin does not equal that of cephaloglycin. However, excellent oral absorption and lack of serum binding of cephalexin compensates significantly for the lower in vitro activity. Exceptional efficacy against experimental bacterial infections in mice was obtained with cephalexin therapy as compared with cephaloglycin, tetracycline, and chloramphenicol. The data suggest that cephalexin merits clinical trial.
一种与头孢甘氨酸结构相关的新型抗生素,已被赋予通用名头孢氨苄,即7-(D-α-氨基-α-苯乙酰胺基)-3-甲基-3-头孢烯-5-羧酸。头孢氨苄的体外抗菌活性不如头孢甘氨酸。然而,头孢氨苄出色的口服吸收性和缺乏血清结合性显著弥补了其较低的体外活性。与头孢甘氨酸、四环素和氯霉素相比,头孢氨苄治疗对小鼠实验性细菌感染具有卓越疗效。数据表明头孢氨苄值得进行临床试验。